Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Google Secures Pentagon AI Deal for Classified Projects 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
HOUSTON, May 04, 2017 -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 11, 2017 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2017, and to provide a business overview.
To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time, and refer to conference ID 11686674. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Contact Information: Investors Will O’Connor Stern Investor Relations 212-362-1200 [email protected] Doug Morris Investor Relations Bio-Path Holdings, Inc. 832-742-1369
